拉萨米德含有硫尼尔皮佩拉辛作为有效的药物,用于控制与眼相关的症状
Jaydeo T Kilbile1, Suryakant B Sapkal1, Gioele Renzi2
1Department of Chemistry, School of Basic and Applied Sciences, MGM University, Chhatrapati Sambhajinagar, 431003, MS, India.
ChemMedChem
|September 25, 2024
概括
新的拉萨米德衍生物通过抑制二氧化碳无水酶II的作用,显示出对治疗青光眼的强大潜力. 化合物7和9在动物模型中有效,其中一个持续长达4小时.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 二氧化碳无水酶II (CA-II) 是调节眼内压力 (IOP) 的关键酶.
- 升高的内压是青光眼的主要风险因素,是不可逆转失明的主要原因.
- 开发选择性CA-II抑制剂对于有效的绿眼病管理至关重要.
研究的目的:
- 设计和合成基于拉萨米德支架的新硫胺衍生物.
- 评估这些化合物的抑制效能和选择性,以对抗人类的二氧化碳无水酶.
- 在绿眼动物模型中评估有前途的候选药物的体内疗效.
主要方法:
- 2,4-二-5-{[4-(phenylsulfonyl) piperazin-1-yl]carbonyl}二胺基通过用替代的 piperazines 进行拉萨米德 1 的化合成.
- 在体外酶分析以确定阻碍常量 (Ki) 和针对CA-II的选择性概况.
- 在动物格劳科马模型中的体内研究,以评估IOP降低效果和作用持续时间.
主要成果:
- 一系列新的拉萨米德衍生物成功合成和特征化.
- 这些化合物显著抑制了人类的二氧化碳无水酶II,具有很高的选择性.
- 选择的化合物,特别是化合物9,在体内表现出有希望的IOP降低效果,持续作用长达4小时.
结论:
- 拉萨米德衍生物代表了一种有前途的新类化合物,用于治疗眼.
- 合成的化合物表现出CA-II的强大和选择性抑制.
- 这些衍生品的进一步开发可能会导致管理高IOP的新疗法策略.
相关概念视频
01:27Open Angle Glaucoma: Treatment
406
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
406
01:17Oral Hypoglycemic Agents: Sulfonylureas
196
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
196
01:28Angle Closure Glaucoma: Treatment
451
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
451
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
558
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
558
01:25Glaucoma: Overview
528
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
528
01:06Oral Hypoglycemic Agents: Glinides
145
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
145